The Pharmacokinetic and Pharmacodynamic Properties of Hydroxychloroquine and Dose Selection for COVID-19: Putting the Cart Before the Horse

Coronavirus disease 2019 (COVID-19), caused by the 2019 novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is currently responsible for a global pandemic. To date, only remdesivir and dexamethasone have demonstrated a positive response in a prospective, randomized trial for the trea...

Descripción completa

Detalles Bibliográficos
Autores principales: Morrisette, Taylor, Lodise, Thomas P., Scheetz, Marc H., Goswami, Srijib, Pogue, Jason M., Rybak, Michael J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7395206/
https://www.ncbi.nlm.nih.gov/pubmed/32740858
http://dx.doi.org/10.1007/s40121-020-00325-2
_version_ 1783565365004992512
author Morrisette, Taylor
Lodise, Thomas P.
Scheetz, Marc H.
Goswami, Srijib
Pogue, Jason M.
Rybak, Michael J.
author_facet Morrisette, Taylor
Lodise, Thomas P.
Scheetz, Marc H.
Goswami, Srijib
Pogue, Jason M.
Rybak, Michael J.
author_sort Morrisette, Taylor
collection PubMed
description Coronavirus disease 2019 (COVID-19), caused by the 2019 novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is currently responsible for a global pandemic. To date, only remdesivir and dexamethasone have demonstrated a positive response in a prospective, randomized trial for the treatment of patients with COVID-19. Hydroxychloroquine (HCQ) is an agent available in an oral formulation with in vitro activity against SARS-CoV-2 that has been suggested as a potential agent. Unfortunately, results of randomized trials evaluating HCQ as treatment against a control group are lacking, and little is known about its pharmacokinetic/pharmacodynamic (PK/PD) profile against SARS-CoV-2. The objective of this review was to describe the current understanding of the PK/PD and dose selection of HCQ against SARS-CoV-2, discuss knowledge gaps, and identify future studies that are needed to optimize the efficacy and safety of treatments against COVID-19.
format Online
Article
Text
id pubmed-7395206
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Springer Healthcare
record_format MEDLINE/PubMed
spelling pubmed-73952062020-08-03 The Pharmacokinetic and Pharmacodynamic Properties of Hydroxychloroquine and Dose Selection for COVID-19: Putting the Cart Before the Horse Morrisette, Taylor Lodise, Thomas P. Scheetz, Marc H. Goswami, Srijib Pogue, Jason M. Rybak, Michael J. Infect Dis Ther Review Coronavirus disease 2019 (COVID-19), caused by the 2019 novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is currently responsible for a global pandemic. To date, only remdesivir and dexamethasone have demonstrated a positive response in a prospective, randomized trial for the treatment of patients with COVID-19. Hydroxychloroquine (HCQ) is an agent available in an oral formulation with in vitro activity against SARS-CoV-2 that has been suggested as a potential agent. Unfortunately, results of randomized trials evaluating HCQ as treatment against a control group are lacking, and little is known about its pharmacokinetic/pharmacodynamic (PK/PD) profile against SARS-CoV-2. The objective of this review was to describe the current understanding of the PK/PD and dose selection of HCQ against SARS-CoV-2, discuss knowledge gaps, and identify future studies that are needed to optimize the efficacy and safety of treatments against COVID-19. Springer Healthcare 2020-08-01 2020-09 /pmc/articles/PMC7395206/ /pubmed/32740858 http://dx.doi.org/10.1007/s40121-020-00325-2 Text en © The Author(s) 2020 Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.
spellingShingle Review
Morrisette, Taylor
Lodise, Thomas P.
Scheetz, Marc H.
Goswami, Srijib
Pogue, Jason M.
Rybak, Michael J.
The Pharmacokinetic and Pharmacodynamic Properties of Hydroxychloroquine and Dose Selection for COVID-19: Putting the Cart Before the Horse
title The Pharmacokinetic and Pharmacodynamic Properties of Hydroxychloroquine and Dose Selection for COVID-19: Putting the Cart Before the Horse
title_full The Pharmacokinetic and Pharmacodynamic Properties of Hydroxychloroquine and Dose Selection for COVID-19: Putting the Cart Before the Horse
title_fullStr The Pharmacokinetic and Pharmacodynamic Properties of Hydroxychloroquine and Dose Selection for COVID-19: Putting the Cart Before the Horse
title_full_unstemmed The Pharmacokinetic and Pharmacodynamic Properties of Hydroxychloroquine and Dose Selection for COVID-19: Putting the Cart Before the Horse
title_short The Pharmacokinetic and Pharmacodynamic Properties of Hydroxychloroquine and Dose Selection for COVID-19: Putting the Cart Before the Horse
title_sort pharmacokinetic and pharmacodynamic properties of hydroxychloroquine and dose selection for covid-19: putting the cart before the horse
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7395206/
https://www.ncbi.nlm.nih.gov/pubmed/32740858
http://dx.doi.org/10.1007/s40121-020-00325-2
work_keys_str_mv AT morrisettetaylor thepharmacokineticandpharmacodynamicpropertiesofhydroxychloroquineanddoseselectionforcovid19puttingthecartbeforethehorse
AT lodisethomasp thepharmacokineticandpharmacodynamicpropertiesofhydroxychloroquineanddoseselectionforcovid19puttingthecartbeforethehorse
AT scheetzmarch thepharmacokineticandpharmacodynamicpropertiesofhydroxychloroquineanddoseselectionforcovid19puttingthecartbeforethehorse
AT goswamisrijib thepharmacokineticandpharmacodynamicpropertiesofhydroxychloroquineanddoseselectionforcovid19puttingthecartbeforethehorse
AT poguejasonm thepharmacokineticandpharmacodynamicpropertiesofhydroxychloroquineanddoseselectionforcovid19puttingthecartbeforethehorse
AT rybakmichaelj thepharmacokineticandpharmacodynamicpropertiesofhydroxychloroquineanddoseselectionforcovid19puttingthecartbeforethehorse
AT morrisettetaylor pharmacokineticandpharmacodynamicpropertiesofhydroxychloroquineanddoseselectionforcovid19puttingthecartbeforethehorse
AT lodisethomasp pharmacokineticandpharmacodynamicpropertiesofhydroxychloroquineanddoseselectionforcovid19puttingthecartbeforethehorse
AT scheetzmarch pharmacokineticandpharmacodynamicpropertiesofhydroxychloroquineanddoseselectionforcovid19puttingthecartbeforethehorse
AT goswamisrijib pharmacokineticandpharmacodynamicpropertiesofhydroxychloroquineanddoseselectionforcovid19puttingthecartbeforethehorse
AT poguejasonm pharmacokineticandpharmacodynamicpropertiesofhydroxychloroquineanddoseselectionforcovid19puttingthecartbeforethehorse
AT rybakmichaelj pharmacokineticandpharmacodynamicpropertiesofhydroxychloroquineanddoseselectionforcovid19puttingthecartbeforethehorse

Ejemplares similares